# Aurobindo Pharma has received the green light from the US Food & Drug Administration to produce and market its dapagliflozin tablets.

*biotech · news · 2026-04-07 · Devdiscourse*

## Key points

- Aurobindo Pharma received FDA approval to produce generic dapagliflozin tablets for type 2 diabetes.
- The approved generic is bioequivalent and therapeutically equivalent to AstraZeneca's Farxiga.
- Aurobindo secured 180 days of shared generic marketing exclusivity for dapagliflozin in the US.
- The US market size for dapagliflozin is estimated at USD 10.2 billion as of February 2026.

**Companies:** Aurobindo Pharma
**Countries:** United States, India

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3865416-aurobindo-pharma-gains-usfda-nod-for-diabetes-drug)

---

Canonical: https://newsio.io/n/4a6920d9-20a5-40df-a353-e53a0dc53e1e/aurobindo-pharma-has-received-the-green-light-from-the-us-food-drug-administrati
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works